Pipeline and clinical development risk
Drug candidates may fail in trials, miss endpoints, or be delayed by regulators.
- Scope
- Oncology, rare disease, and specialty pipeline assets
- Materiality
- high
AstraZeneca
AstraZeneca is a UK-based biopharmaceutical company that discovers, develops, manufactures, and commercialises prescription medicines worldwide. Its portfolio spans oncology, rare disease, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology therapies, with operations in more than 100 countries.
0.94
0.65
| % | |
|---|---|
| Oncology | 40% Cancer medicines across multiple tumor types and treatment settings. |
| BioPharmaceuticals | 35% Cardiovascular, renal & metabolism, and respiratory & immunology medicines. |
| Rare Disease | 15% Specialty therapies for rare and often severe chronic conditions. |
| Collaboration Revenue | 10% Milestones, royalties, and other income from partnered programs. |
AstraZeneca sells primarily to healthcare systems, hospitals, clinics, and pharmacies that dispense prescription...
- Hospitals and cancer centersprimary
Buy oncology medicines for use in specialist treatment pathways and infusion settings.
- Specialist physicians and clinicsprimary
Prescribe respiratory, renal, cardiovascular, and rare disease therapies for chronic care.
- Payers and public health systemsprimary
Influence access through reimbursement, formulary placement, and procurement decisions.
- Government and multilateral buyerssecondary
Purchase vaccines and public-health products through advance purchase or supply agreements.
- Biopharma collaboration partnerssecondary
Share development, manufacturing, and commercialization economics on partnered assets.
AstraZeneca operates globally, with commercial activity in more than 100 countries and a base in Cambridge, UK...
- •Headquartered in Cambridge, United Kingdom
- •Commercial operations span more than 100 countries
- •Large exposure to North America, Europe, and Asia
- •Emerging markets contribute to product mix and access
- •Global manufacturing and supply chains support worldwide launches
AstraZeneca’s strategy centers on advancing a deep pipeline, expanding launches in core therapeutic areas, and using...
01
Pipeline advancement and launch executionshort-term
Future growth depends on successful clinical readouts, approvals, and commercialization of new medicines.
02
Manufacturing and supply expansionshort-term
Global demand and complex biologics require reliable capacity and compliant supply.
03
Business development and portfolio buildingmedium-term
Acquisitions and collaborations add new technologies, modalities, and future revenue streams.
04
Capital discipline and shareholder returnsmedium-term
The company balances reinvestment with credit quality and a progressive dividend policy.
AstraZeneca faces typical biopharma risks tied to clinical development, regulatory approval, patent protection, and the...
Intellectual property and patent challenges
Loss of exclusivity or adverse IP rulings can accelerate generic or biosimilar competition.
- Scope
- Key marketed medicines and future launches
- Materiality
- high
Pricing, affordability, and access pressure
Payers and governments can restrict reimbursement or negotiate lower prices.
- Scope
- Global prescription medicine portfolio
- Materiality
- high
Manufacturing and supply-chain execution
Biologics and global distribution require compliant, uninterrupted supply.
- Scope
- Global production and third-party suppliers
- Materiality
- high
Legal and regulatory compliance
Product liability, antitrust, and anti-corruption issues can lead to fines or restrictions.
- Scope
- Commercial practices and marketed medicines
- Materiality
- medium
Collaboration revenue and milestone recognition
Affects quarterly comparability and revenue mix
Profit-sharing arrangements
Influences gross margin and cost of sales
Business combination valuation
Affects goodwill, intangible assets, and future amortization
Contingent liabilities and legal provisions
Can materially affect expenses and balance sheet reserves
Foreign exchange hedging
Affects earnings timing and OCI
: 11/08/2026